Does the Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Improve in Vitro Fertilization Cycles Outcome? A Clinical Trial Study

Overview

Journal Int J Reprod Biomed

Specialty Reproductive Medicine

Date 2020 Aug 18

PMID 32803113

Citations 4

Authors

Abbas Aflatoonian

Fatemeh Haghighi

Masrooreh Hoseini

Saeid Haghdani

Affiliations

Soon will be listed here.

Abstract

Background: A repeat dose of Gonadotropin-releasing Hormone (GnRH) agonist could provide long duration of luteinizing hormone (LH) surge and amplitude appropriately.

Objective: Improvement in oocyte maturity could be obtained by a repeat dose of GnRH agonist.

Materials And Methods: In this randomized double-blinded study, 120 women with polycystic ovarian syndrome and serum estradiol level (E2) 3000 who were candidate for in vitro fertilization with Antagonist protocol were enrolled between July 2018 and July 2019. Participants were randomized in two groups - and final oocyte maturation was triggered with two doses: In group A, a repeat dose of 0.1 mg, 12 hr. after the first dose and in group B, 0.2 mg SC triptorelin (decapeptyl) 35 hr. prior to oocyte retrieval. Serum Estradiol, LH, and progesterone concentration were measured on the trigger day. Serum LH measurement was done three times in both groups. The outcomes were oocyte yield, meiosis (M) I, MII, Maturity rate, germinal vesicle (GV) rate, 2 pronuclear, embryo yield, ovarian hyper stimulation syndrome rates.

Results: Maturity rate (p = 0.89), MI (p = 0.38), MII (p = 0.89), and GV oocytes (p = 0.38) were not statistically different between the two study groups. LH levels measured at 12 hr post-trigger did not relate statistically significant with maturity rate in our participants (p = 0.96). No empty follicular syndrome was reported.

Conclusion: Although, the second dose of GnRH agonist after 12 hr since the first dose could provide duration of LH surge and amplitude and as a result no empty follicular syndrome was seen, the maturity rate, MI, MII, and GV oocytes were not different between the two study groups.

Citing Articles

A repeated gonadotropin-releasing hormone agonist trigger improves pregnancy outcomes of frozen-thawed embryo transfer in GnRH antagonist cycles: a retrospective propensity-matched score analysis.

Wang A, Zhou X, Lai Y, Ma L, Zhang J, Huang S J Assist Reprod Genet. 2024; 41(12):3433-3443.

PMID: 39487904 PMC: 11707104. DOI: 10.1007/s10815-024-03269-5.

Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial.

Hashemi S, Hafezi M, Arabipoor A, Zareei M, Vesali S, Eftekhari-Yazdi P Int J Fertil Steril. 2024; 18(Suppl 1):48-54.

PMID: 39033370 PMC: 11263846. DOI: 10.22074/ijfs.2023.2008905.1513.

Ovarian protection and safety of gonadotropin-releasing hormone agonist after cervical cancer surgery: systematic review and meta-analysis.

Yuan J, Lai Y, Li T Ann Transl Med. 2022; 10(7):409.

PMID: 35530944 PMC: 9073801. DOI: 10.21037/atm-22-928.

Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Ganer Herman H, Horowitz E, Mizrachi Y, Farhi J, Raziel A, Weissman A J Assist Reprod Genet. 2022; 39(2):291-303.

PMID: 35306603 PMC: 8956771. DOI: 10.1007/s10815-021-02359-y.

References

Humaidan P, Papanikolaou E, Kyrou D, Alsbjerg B, Polyzos N, Devroey P . The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online. 2011; 24(2):134-41. DOI: 10.1016/j.rbmo.2011.11.001. View

Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes J . Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991; 56(2):213-20. View

Itskovitz-Eldor J, Kol S, Mannaerts B . Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation.... Hum Reprod. 2000; 15(9):1965-8. DOI: 10.1093/humrep/15.9.1965. View

Yen S, Llerena O, Little B, Pearson O . Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab. 1968; 28(12):1763-7. DOI: 10.1210/jcem-28-12-1763. View

Gonen Y, Balakier H, Powell W, Casper R . Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990; 71(4):918-22. DOI: 10.1210/jcem-71-4-918. View

Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C . The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective.... Fertil Steril. 2007; 89(1):84-91. DOI: 10.1016/j.fertnstert.2007.02.002. View

Eppig J . FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatory follicles. Nature. 1979; 281(5731):483-4. DOI: 10.1038/281483a0. View

Seibel M, Smith D, Levesque L, Borten M, TAYMOR M . The temporal relationship between the luteinizing hormone surge and human oocyte maturation. Am J Obstet Gynecol. 1982; 142(5):568-72. DOI: 10.1016/0002-9378(82)90763-3. View

Deepika K, Sindhuma D, Kiran B, Ravishankar N, Gautham P, Kamini R . Empty Follicle Syndrome Following GnRHa Trigger in PCOS Patients Undergoing IVF Cycles. J Reprod Infertil. 2018; 19(1):16-25. PMC: 5960047. View

10.

Deepika K, Baiju P, Gautham P, Suvarna R, Arveen V, Kamini R . Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Undergoing Fertilization Cycles Provides a Better Cycle Outcome - A proof-of-concept Study. J Hum Reprod Sci. 2018; 10(4):271-280. PMC: 5799931. DOI: 10.4103/jhrs.JHRS_102_17. View

11.

Kol S . Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004; 81(1):1-5. DOI: 10.1016/j.fertnstert.2003.05.032. View

12.

Andersen C . Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online. 2002; 5(3):232-9. DOI: 10.1016/s1472-6483(10)61826-3. View

13.

Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S . Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective.... Fertil Steril. 2011; 95(6):2029-33, 2033.e1. DOI: 10.1016/j.fertnstert.2011.01.163. View

14.

ONeill K, Senapati S, Dokras A . Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome. Fertil Steril. 2014; 103(1):264-9. PMC: 4866644. DOI: 10.1016/j.fertnstert.2014.09.042. View

15.

Castillo J, Garcia-Velasco J, Humaidan P . Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. J Assist Reprod Genet. 2012; 29(3):249-53. PMC: 3288136. DOI: 10.1007/s10815-011-9704-8. View

16.

Humaidan P, Kol S, Papanikolaou E . GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Hum Reprod Update. 2011; 17(4):510-24. DOI: 10.1093/humupd/dmr008. View

17.

Moyle W, BAHL O, Marz L . Role of carbohydrate of human chorionic gonadotropin in the mechanism of hormone action. J Biol Chem. 1975; 250(23):9163-9. View